NHIA submitted comments on California SB 958, the Medication and Patient Safety Act of 2022, supporting amendments to the proposed legislation that allow for infused medications to be administered in the enrollee’s home when the physician and patient determine it…
NHIA submitted comments on a CMS proposed rule: Medicare and Medicaid Programs; CY 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs, which would alter the way pharmacy price concessions, including direct and indirect…
CMS recently issued a report which summarizes utilization trends for the Medicare Part B home infusion therapy (HIT) services benefit indicating the benefit has failed to draw sufficient participation from providers to ensure equitable access to beneficiaries across the U.S.